case report | Q2782326 |
scholarly article | Q13442814 |
P50 | author | Wiesław Jerzy Cubała | Q57009712 |
Mariusz Wiglusz | Q84416902 | ||
Alina Wilkowska | Q85907507 | ||
P2860 | cites work | Do Atypical Antipsychotics Have Antisuicidal Effects? A Hypothesis-Generating Overview | Q28077687 |
Suicidal risk during treatment with clozapine: a meta-analysis | Q33984401 | ||
Existing and novel biological therapeutics in suicide prevention | Q34085866 | ||
Intracellular modulation of NMDA receptor function by antipsychotic drugs | Q34372226 | ||
Real-world effectiveness of clozapine in patients with bipolar disorder: results from a 2-year mirror-image study | Q34644698 | ||
The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder | Q34649187 | ||
Clozapine for Treatment-Refractory Schizophrenia, Schizoaffective Disorder, and Psychotic Bipolar Disorder | Q60633571 | ||
Clozapine for treatment-refractory mania | Q71085936 | ||
Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up | Q72152369 | ||
Clozapine associated with decreased suicidality in bipolar disorder: a case report | Q73625587 | ||
Suicide in bipolar disorder: Risks and management. | Q36525750 | ||
Suicide risk in depression and bipolar disorder: Do impulsiveness-aggressiveness and pharmacotherapy predict suicidal intent? | Q36836763 | ||
Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology | Q37426143 | ||
International Society for Bipolar Disorders Task Force on Suicide: meta-analyses and meta-regression of correlates of suicide attempts and suicide deaths in bipolar disorder. | Q38261404 | ||
Clozapine for treatment-resistant bipolar disorder: a systematic review. | Q38262870 | ||
Clozapine in severe mood disorders | Q40476928 | ||
The effects of clozapine versus haloperidol on measures of impulsive aggression and suicidality in chronic schizophrenia patients: an open, nonrandomized, 6-month study. | Q42606780 | ||
Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania | Q42608014 | ||
Low doses of clozapine may stabilize treatment-resistant bipolar patients | Q42640390 | ||
Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). | Q44268852 | ||
Early age at onset as a risk factor for poor outcome of bipolar disorder | Q44295348 | ||
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. | Q45484599 | ||
Psychiatrists' attitude towards and knowledge of clozapine treatment | Q46150844 | ||
Exploratory investigation of biomarker candidates for suicide in schizophrenia and bipolar disorder | Q47788587 | ||
Clozapine markedly elevates pregnenolone in rat hippocampus, cerebral cortex, and serum: candidate mechanism for superior efficacy? | Q48424732 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P921 | main subject | bipolar disorder | Q131755 |
P304 | page(s) | 520 | |
P577 | publication date | 2019-07-19 | |
P1433 | published in | Frontiers in Psychiatry | Q27723495 |
P1476 | title | Clozapine in Treatment-Resistant Bipolar Disorder With Suicidality. Three Case Reports | |
P478 | volume | 10 |
Search more.